Avidity Partners Management LP Prothena Corp Public LTD CO Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $7.22 Million - $10.8 Million	-152,695 Reduced 28.54%	382,305 $18.4 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $25.7 Million - $41.9 Million	-533,200 Reduced 49.92%	535,000 $36.5 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $88.5 Million - $110 Million	-1,884,800 Reduced 63.83%	1,068,200 $51.8 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $51.3 Million - $64.1 Million	986,000 Added 50.13%	2,953,000 $178 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $49.5 Million - $119 Million	1,967,000 New	1,967,000 $119 Million
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $8.77 Million - $14.4 Million	-182,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $3.94 Million - $10.5 Million	182,000 New	182,000 $9.36 Million

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.